<DOC>
	<DOCNO>NCT00005788</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill lymphoma cell . PURPOSE : Phase II trial study effectiveness interleukin-2 treating patient mycosis fungoides Sezary syndrome .</brief_summary>
	<brief_title>Interleukin-2 Treating Patients With Mycosis Fungoides Sezary Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient mycosis fungoides Sezary syndrome treat interleukin-2 ( IL-2 ) . - Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients receive interleukin-2 subcutaneously 4 consecutive day week 6 consecutive week . Treatment repeat every 8 week absence disease progression unacceptable toxicity . Patients achieve complete response stable disease continue treatment 2 course past best response . Patients demonstrate persistent partial response continue treatment absence disease progression unacceptable toxicity . Patients follow every 3 month survival . PROJECTED ACCRUAL : A total 15-35 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven mycosis fungoides Sezary syndrome Any stage Measurable disease 1 indicator lesion Evaluable disease erythrodermic patient At least 2 week since prior therapy , document progressive disease ( PD ) At least 4 week since prior therapy , best response achieve without clear evidence PD PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : WBC least 3,000/mm^3 Absolute granulocyte count least 1,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2.2 mg/dL Renal : Creatinine great 2.0 mg/dL Cardiovascular : No New York Heart Association class III IV heart disease No cardiac pacemaker No clinically significant peripheral venous insufficiency Other : No malignancy within past 5 year except : Treated squamous cell basal cell skin cancer Treated carcinoma situ cervix Surgically treat cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection HIV negative No poorly control diabetes mellitus PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : No concurrent steroids Radiotherapy : See Disease Characteristics No concurrent radiotherapy Surgery : Not specify Other : No concurrent proven investigational antineoplastic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
</DOC>